CIRM Funded Clinical Trials

A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML

Disease Area:
Leukemia, Acute Myeloid (AML)
CIRM Grant:
CLIN2-09574 (Closed)
Award Value:
Trial Sponsor:
Trial Stage:
Phase 2
Trial Status:
Targeted Enrollment:
146 ID:


Nohla Therapeutics is testing a hematopoietic stem cell and progenitor cell therapy called NLA101 to help patients suffering from neutropenia, a condition that leaves people susceptible to deadly infections, after receiving chemotherapy for acute myeloid leukemia (AML). The company is currently launching a Phase 2 trial to test this treatment in adult AML patients that have received high-dose chemotherapy.


Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy.


Evaluate effect on the rate of infections associated with Chemotherapy-Induced Neutropenia in AML patients and determine optimal dose of cell therapy.

News about this clinical trial:

Contact Trial Sponsor

CIRM Clinical Trial Resources

Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox

Video on Stem Cell Trials

Other Resources

ISSCR Patient Website